Symbols

VIR

Vir Biotechnology·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VIR

Vir Biotechnology, Inc.

A biotech company developing innovative treatments for infectious diseases, including hepatitis B and COVID-19

Industry

Biological Technology

Established Date

04/07/2016

Listing Date

10/11/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

367

Fiscal Year Ends

12-31

Website

www.vir.bio

Security Type

Common stock

Office address

1800 Owens Street, Suite 900, San Francisco, California 94158

Business

Introduction

Vir Biotechnology, Inc., was incorporated under the laws of the State of Delaware on April 7, 2016. As a clinical-stage biopharmaceutical company, VIR is committed to boosting the immune system to develop innovative therapies for serious infectious diseases and cancer. The company's approach focuses on addressing the complex mechanisms by which these threats evade immune defense. Vir's clinical development pipeline includes therapies for delta hepatitis virus and various solid tumors, and ongoing clinical programs and trials show promise for new standards of care. The company utilizes its proprietary technology platforms DAISY and PRO-XTEN to optimize antibody development. With a leadership team experienced in immunology, infectious diseases and oncology, VIR is committed to changing lives through its transformative therapies.

Company Financials

EPS

VIR has released its 2025 Q4 earnings. EPS was reported at -0.31, versus the expected -0.54, beating expectations. The chart below visualizes how VIR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VIR has released its 2025 Q4 earnings report, with revenue of 64.07M, reflecting a YoY change of 417.78%, and net profit of -42.92M, showing a YoY change of 58.96%. The Sankey diagram below clearly presents VIR's revenue sources and cost distribution.